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tive Real-time PCR to analyse EGFR gene copy number using the ABI 
7000 sequence detection system. The same specimens are analysed to 
identify expression of EGFR using standard immunohistochemistry 
techniques. 
Results: 100 samples have been analysed to date. EGFR mutations 
occurred in ~6% of these. K-ras mutations occurred in ~8%. EGFR 
overexpression occurred in ~40%. Data including gene copy number 
from the complete cohort of patients will be linked to survival and 
other clinical parameters. 
Conclusion: The level of mutations in the EGFR are low. This may be 
explained by the fact that our study population was entirely Caucasian, 
predominantly smokers or ex smokers and the tumour sample popula-
tion was not enriched for adenocarcinoma. The K-ras mutation rate is 
consistent with a predominantly smoking population. The detection 
of these mutations in the future may become important determinant in 
the selection of therapy as there is some evidence to suggest that K-ras 
mutated tumours are not only resistant to the TKI’s but also their growth 
may be accelerated with TKI treatment. The relevance of determining 
EGFR gene copy number using RT-PCR technology is as yet unclear but 
a planned survival analysis may determine its prognostic signiﬁcance.
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Purpose: Recent studies have challenged the previously postulated 
concept of a tumor-suppressive effect of Carcinoembryonic Antigen-
related Cell Adhesion Molecule 1 (CEACAM-1). A possible angiogenic 
inﬂuence of CEACAM-1 in non small-cell lung cancer (NSCLC) 
has not been investigated so far. Therefore, we examined microves-
sel density (MVD) and CEACAM-1 expression in primary NSCLC 
and analyzed their possible correlations under consideration of their 
prognostic effects.
Patients and methods: Specimens from 82 consecutive patients with 
completely resected NSCLC were stained immunohistochemically 
using the monoclonal anti-CEACAM-1 antibody 4D1/C2 and the 
monoclonal anti-CD31 antibody JC70A. The prognostic relevance of 
CEACAM-1 expression and MVD was evaluated by univariate Kaplan-
Meier and multivariate Cox regression analysis. The median follow-up 
period was 75 months (range 10 to 156 months).
Results: A high MVD (i.e.≥31 microvessels/x400 microscopic ﬁeld) 
was observed more frequently in tumors with high CEACAM-1 
expression (i.e.≥66% stained tumor cells) than in tumors with low 
CEACAM-1 expression (61.8 versus 33.3%, respectively; p=0.01). In 
univariate survival analyses, high CEACAM-1 expression and high 
MVD were associated with development of distant metastasis (p=0.011 
and 0.022 respectively) and decreased cancer-related survival (p=0.046 
and p=0.006 respectively). Multivariate Cox regression analysis 
demonstrated that the prognostic impact of CEACAM-1 depended on 
the prognostic inﬂuence of MVD, while MVD itself represented an 
independent prognosticator for unfavorable cancer-related survival 
(p=0.021; relative risk, 2.1; 95% conﬁdence interval, 1.1-4.0).
Conclusion: Here we show for the ﬁrst time that high CEACAM-1 ex-
pression is associated with an increased angiogenic activity in NSCLC, 
and that the prognostic inﬂuence of CEACAM-1 might be derived from 
this association. 
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Background: To examine recent gene and protein expression proﬁling 
reports and a meta analysis of Thyroid Transcription Factor 1 protein 
expression for reproducibility as prognostic factors for survival, using 
two online Lung Cancer Micro array data sources as having prognostic 
potential in early Adenocarcinaoma of the Lung. To assess whether 
a poor prognostic grouping can be divided into treatment prognostic 
subgroups by genes selected for 5 Fluorouracil sensitivity or resistance. 
Methods: Two online micro array data sets were used to assess 
reproducibility of reported proﬁles of prognostic signatures. The gene 
probe for TTF1 was examined for survival association in the two data 
sets. Genes found to be signiﬁcant for survival in the ﬁrst data set were 
tested in a separate test group. Gene probes found to be signiﬁcant in 
both groupings were assessed, as a categorized variables, for predicting 
survival.
Results: The high expression of a probe for the gene procollagen-ly-
sine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2) and the low expression 
of a probe for TTF1 gene were signiﬁcant and increased the hazard for 
a poor survival. The signiﬁcance was seen in both micro array data sets.
The hazard for PLOD2, 95% CI 1.14 to 2.13 and for TTF1 0.51 to 0.98. 
PLOD2 was a better discriminator for survival to 18, 24 or 30 months. 
PLOD2 gene expression but not TTF1 remained an important variable 
if age, sex, grade, size or bronchoalveolar features were examined as 
covariables.
That genes possibly important in 5FU sensitivity can be used to cluster 
patients with a poor prognostic high PLOD2 expression or low TTF1 
expression.
Conclusion: That TTF1 has achieved further proof as a prognostic 
factor in early Adenocarcinomas of the lung. That PLOD2 a gene as-
sociated with a ﬁbroblastic response to serum might be important in 
early cancer progression in Adenocarcinoma of the lung and deserves 
further investigation. That patient categorization using prognostic genes 
for 5FU sensitivity is possible and should be considered in a prospec-
tive trial.
